KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) FCF Margin (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed FCF Margin for 11 consecutive years, with 5834.04% as the latest value for Q3 2024.

  • On a quarterly basis, FCF Margin rose 608292.0% to 5834.04% in Q3 2024 year-over-year; TTM through Dec 2024 was 180000.0%, a 18012057.0% decrease, with the full-year FY2024 number at 2511.63%, up 284593.0% from a year prior.
  • FCF Margin was 5834.04% for Q3 2024 at Palvella Therapeutics, up from 26716.67% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 5834.04% in Q3 2024 to a low of 26716.67% in Q2 2024.
  • A 5-year average of 1351.86% and a median of 172.35% in 2022 define the central range for FCF Margin.
  • Biggest YoY gain for FCF Margin was 608292bps in 2024; the steepest drop was -2664992bps in 2024.
  • Palvella Therapeutics' FCF Margin stood at 921.94% in 2020, then skyrocketed by 90bps to 95.47% in 2021, then tumbled by -120bps to 210.39% in 2022, then soared by 74bps to 55.15% in 2023, then skyrocketed by 10679bps to 5834.04% in 2024.
  • Per Business Quant, the three most recent readings for PVLA's FCF Margin are 5834.04% (Q3 2024), 26716.67% (Q2 2024), and 2344.68% (Q1 2024).